GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipca Laboratories Ltd (NSE:IPCALAB) » Definitions » Debt-to-Revenue

Ipca Laboratories (NSE:IPCALAB) Debt-to-Revenue : 0.13 (As of Sep. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Ipca Laboratories Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Ipca Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₹7,097 Mil. Ipca Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₹4,925 Mil. Ipca Laboratories's annualized Revenue for the quarter that ended in Sep. 2024 was ₹94,196 Mil. Ipca Laboratories's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 0.13.


Ipca Laboratories Debt-to-Revenue Historical Data

The historical data trend for Ipca Laboratories's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipca Laboratories Debt-to-Revenue Chart

Ipca Laboratories Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.05 0.14 0.24 0.19

Ipca Laboratories Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 - 0.18 - 0.13

Competitive Comparison of Ipca Laboratories's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Ipca Laboratories's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ipca Laboratories's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ipca Laboratories's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ipca Laboratories's Debt-to-Revenue falls into.



Ipca Laboratories Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Ipca Laboratories's Debt-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(8180.2 + 6203.4) / 76224.1
=0.19

Ipca Laboratories's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(7097 + 4924.8) / 94196
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


Ipca Laboratories Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ipca Laboratories's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ipca Laboratories Business Description

Traded in Other Exchanges
Address
125, Kandivli Industrial Estate, Kandivli (West), Mumbai, MH, IND, 400067
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.

Ipca Laboratories Headlines

No Headlines